Norah L. Henry, MD, reviews key updates on metastatic HR-positive, HER2-negative breast cancer that were presented at this year’s San Antonio Breast Cancer Symposium. The PADMA trial showed that combining endocrine therapy with palbociclib resulted in an 11-month improvement in time to treatment failure compared with chemotherapy, supporting this approach for high-risk patients. The EMBER-3 trial examined the oral SERD imlunestrant, which showed slightly better progression-free survival (PFS) than standard therapies, with a 4-month PFS improvement when combined with abemaciclib.
The DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan improved PFS over chemotherapy in ER+, HER2-low metastatic breast cancer. These findings provide important insights into optimizing treatment strategies for these patients, with further analysis needed to refine sequencing and drug combinations.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2024: Key Highlights in HR+/HER2- Breast Cancer - Medscape - Dec 19, 2024.
Comments